Press release: Late-breaking Phase 3 data at AAD 2022 show D

Late-breaking Phase 3 data at AAD 2022 show Dupixent® significantly improved signs and symptoms of prurigo nodularis Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three... | March 26, 2022

Related Keywords

Japan , United States , Paris , France General , France , American , Eva Schaefer Jansen , Corentine Driancourt , Gil Yosipovitch , Felix Lauscher , Vesna Tosic , Hannah Kwagh , Nathalie Pham , Sally Bain , Priya Nanduri , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Dupilumab Development Program , Nasdaq , Teva Pharmaceutical Industries Ltd , Exchange Commission , American Academy Of Dermatology , University Of Miami , Miller School Of Medicine , Euronext , Globenewswire Inc , Late Breaking Phase , Worst Itch Numeric Rating Scale , Global Assessment , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries , Sanofi Stock Exchange , News , Information , Press Release , Hase , , Data , It , Sad , 022 , Show , Ignificantly , Mproved , Signs , End , Symptoms , F , Prurigo , Nodularis , Dupixent , Educed , Pitch , 2 , 4 , Eeks , Early San Fr0000120578 ,